Figure 6 from Exploration of Immune-Modulatory Effects of Amivantamab in Combination with Pembrolizumab in Lung and Head and Neck Squamous Cell Carcinoma

Upregulation of EGFR and MET in HNSCC PDX (YHIM-3003) tumor induced increased expression of immune checkpoints regulators in the EGFRHIGH/METHIGH subcluster (EMHIGH). A, Volcano plot of top 50 genes in EGFRHIGH/METHIGH against EGFRLOW/METLOW tumor subcluster analyzed by log2 fold change (FC) against P-values. Red dots indicating transcripts with significantly increased fold changes including MET, PD-L1, and MET-regulated genes. B, Expression of STAT-4/PD-L1 (MET, STAT4, CD274), MET-regulated (BACE2, STK40, PRSS23, DPYD, CAV1, S100A4, PYGL), and MET-related immune checkpoints (HAVCR2, CD276) generally increased in the EGFRHIGH/METHIGH tumor subcluster compared to the EGFRLOW/METLOW subcluster. C, Expression of MET-related markers in different treatment groups.